| The potential of targeting Wnt/β-catenin in colon cancer A Sebio, M Kahn, HJ Lenz Expert opinion on therapeutic targets 18 (6), 611-615, 2014 | 257 | 2014 |
| Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs V Nogales, WC Reinhold, S Varma, A Martinez-Cardus, C Moutinho, ... Oncotarget 7 (3), 3084, 2016 | 138 | 2016 |
| A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer E Marcuello, D Páez, L Paré, J Salazar, A Sebio, E Del Rio, M Baiget British journal of cancer 105 (1), 53-57, 2011 | 136 | 2011 |
| Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial J Martin-Broto, S Stacchiotti, A Lopez-Pousa, A Redondo, D Bernabeu, ... The Lancet Oncology 20 (1), 134-144, 2019 | 109 | 2019 |
| Molecular pathways: hippo signaling, a critical tumor suppressor A Sebio, HJ Lenz Clinical Cancer Research 21 (22), 5002-5007, 2015 | 79 | 2015 |
| The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal … A Sebio, L Pare, D Paez, J Salazar, A Gonzalez, N Sala, E Del Río, ... Pharmacogenetics and genomics 23 (3), 142-147, 2013 | 71 | 2013 |
| Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors C Serrano, A Vivancos, A López-Pousa, J Matito, FM Mancuso, ... BMC cancer 20, 1-12, 2020 | 42 | 2020 |
| Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer … D Páez, M Tobeña, J Fernández-Plana, A Sebio, AC Virgili, L Cirera, ... British Journal of Cancer 120 (2), 190-195, 2019 | 38 | 2019 |
| Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs). M Riudavets, A Barba, P Maroto, IG Sullivan, G Anguera, D Paez, ... Journal of Clinical Oncology 36 (15_suppl), 3064-3064, 2018 | 33 | 2018 |
| Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work S Stintzing, S Stremitzer, A Sebio, HJ Lenz Hematology/Oncology Clinics 29 (1), 43-60, 2015 | 33 | 2015 |
| Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer Y Sunakawa, S Stremitzer, S Cao, W Zhang, D Yang, T Wakatsuki, Y Ning, ... Annals of Oncology 26 (2), 332-339, 2015 | 28 | 2015 |
| EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer A Sebio, J Salazar, D Paez, A Berenguer-Llergo, E Del Rio, M Tobena, ... The pharmacogenomics journal 15 (1), 77-83, 2015 | 27 | 2015 |
| CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy S Matsusaka, S Cao, DL Hanna, Y Sunakawa, M Ueno, N Mizunuma, ... The pharmacogenomics journal 17 (6), 543-550, 2017 | 21 | 2017 |
| Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan A Sebio, D Páez, J Salazar, A Berenguer-Llergo, L Pare-Brunet, A Lasa, ... The Pharmacogenomics Journal 14 (3), 256-262, 2014 | 21 | 2014 |
| ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients P Riera, A Artigas-Baleri, J Salazar, A Sebio, AC Virgili, MJ Arranz, ... Frontiers in Pharmacology 11, 973, 2020 | 20 | 2020 |
| Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases S Stremitzer, W Zhang, D Yang, Y Ning, S Stintzing, A Sebio, Y Sunakawa, ... Cancer 121 (11), 1898-1905, 2015 | 20 | 2015 |
| Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan‐induced severe toxicity P Riera, J Salazar, AC Virgili, M Tobeña, A Sebio, P Gallano, A Barnadas, ... British journal of clinical pharmacology 84 (6), 1389-1392, 2018 | 19 | 2018 |
| IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from … E Palmerini, A Lopez-Pousa, G Grignani, A Redondo, N Hindi, ... Journal of Clinical Oncology 38 (15_suppl), 11522-11522, 2020 | 17 | 2020 |
| Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer A Sebio, S Matsusaka, W Zhang, D Yang, Y Ning, S Stremitzer, S Stintzing, ... The pharmacogenomics journal 16 (4), 312-319, 2016 | 17 | 2016 |
| Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy L Paré-Brunet, A Sebio, J Salazar, A Berenguer-Llergo, E Río, ... The Pharmacogenomics Journal 15 (5), 397-404, 2015 | 17 | 2015 |
